期刊文献+

聚乙二醇干扰素α-2a与干扰素α-2b治疗慢性丙型肝炎疗效分析 被引量:4

原文传递
导出
摘要 丙型肝炎病毒(HCV)感染可导致肝脏炎症坏死和纤维化,抗病毒治疗是丙型肝炎治疗的根本疗法。我们对慢性丙型肝炎(CHC)患者分别采用聚乙二醇干扰素α-2a(PEG-IFNα-2a)和干扰素α-2b(IFNα-2b)治疗,并对两种干扰素的临床疗效进行对比分析。
出处 《中华实验和临床病毒学杂志》 CAS CSCD 北大核心 2007年第1期89-90,共2页 Chinese Journal of Experimental and Clinical Virology
  • 相关文献

参考文献3

二级参考文献27

  • 1Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non- responders to interferon monotherapy: a meta- analysis of individual patient data[ J ]. Gut, 2002,51:864-869.
  • 2Papatheodoridis GV, Papadimitropoulos VC, Hsdziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus- reated cirrhosis: a meta- analysis[J] .Aliment Pnarmaool Ther, 2001,15:689- 698.
  • 3Kjaergard LL, Krogsgaard K, Gluud C. Interfern alfa with or without ribavirin for chronic hepatitis C: systematic review of randonmised trials[J].BMJ, 2001,323:1151 - 1155.
  • 4Alberti A, Benvegnu L. Management of hepatitis[J] .J Hepatol, 2003,38(Suppl1): S1014 - S1 18.
  • 5Poynard T, MdHutchison J, Davis GL, et al. Impact of interferon alfa - 2b and ribavirin on progression of liver fibrosiis in patients with chronic hepatitis C[J].Hepatology, 2000,32:1131 - 1137.
  • 6Booth JCL, O' Grady J, Neuberger J. Clinical guidelines on the mangement of hepatitis C[J]. Gut, 2001, 49(Suppl I ): il - i12.
  • 7Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systemic review[J]. Hepatology, 2002, 36(5 Suppl 1 ):S135 - S144.
  • 8Di Ciomm no V, Russo P, Rava L, etal. Interferon alpha in the treatment of chronic hepatitis C in children: a mmeta- analysis[J] .J Viral Hepat,2003,10:210 - 214.
  • 9Fabrizi F, Dulai G, DixitV, et al. Meta- analysis: interfeorn for the treatment of chronic hepatitis C in dialysis patients[J] .Aliment Phamacol Ther, 2003,18:1071 - 1081.
  • 10National Institute of Health Consensus Development Conference Panel Statenent. Management of hepatitis C[J].Hepatology, 2002,36(5 Suppl 1):S3- S20.

共引文献773

同被引文献22

  • 1黄海鹏,曾进,李晓东,梅伟.人ACHN肾癌裸鼠移植瘤模型的建立及其特性研究[J].现代肿瘤医学,2005,13(1):32-33. 被引量:4
  • 2崔杨,张树林,蔺淑梅,樊万虎,张忠东,杜方雄.聚乙二醇化干扰素治疗慢性丙型肝炎的疗效观察[J].临床荟萃,2006,21(4):271-272. 被引量:3
  • 3陈青锋,郭振华,肖萍,杨彦麟,熊亚星,岳伟.甘肃地区HCV血清分型与基因分型及干扰素抗体关系研究[J].国际检验医学杂志,2006,27(7):612-614. 被引量:5
  • 4于淑丽,张照华,吕卉,张琴冈,王耀宗.聚乙二醇α-2b干扰素联合利巴韦林治疗慢性丙型肝炎72周随访观察[J].中华肝脏病杂志,2007,15(3):231-231. 被引量:6
  • 5[4]Michallet M,Maloisel F,Delain M,et al.Pegylated recombinant interferon alpha-2b vs recombinant interferon alfa-2b for the initial treatment of chronic phase chronic myelogenous leukemia:a phase Ⅲ study[J].Leukemia,2004,18:309-315.
  • 6[5]Bukowski RM,Tendler C,Curler D,et al.Treating cancer with PEG Intron:pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation[J].Cancer,2002,95:389-396.
  • 7[6]Motzer RJ,Rakhit A,Thompson J,et al.Phase Ⅱ trial of branched peginterferon alpha 2a (40kD) for patients with advanced renal cell carcinoma[J].Ann Oncol,2002,13:1799-1805.
  • 8[8]Modi MW,Fulton JS,Buckmann DK,et al.Clearance of pegylated (40Kd) interferon alfa-2a is primarily hepatic[J].Hepatology,2000,32:371A.
  • 9Better C,Fabris P,Zanchetta R,et al.Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therpy in patients with hepatitis C virus chronic infection[J].Dianetes Care,2000,23(8):1177-1181.
  • 10Nemesanszky E,Pusztay M,Csepregi A.Effects of interferon treatment on the glucose metabolism of patients with chronic hepatitis C[J].Eur J Intern Med,2000,11(3):151-155.

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部